Eisai’s Leqembi wins accelerated U.S. approval and unlocks broader Medicare coverage for the drug
Leqembi reduced amyloid markers in early Alzheimer's disease and resulted in moderately less decline in measures of cognition and function ...
Tag: bioactic
